LaNova Medicines Limited Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

LM-061 / LaNova Medicines Limited

NCT04882176: A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Terminated

1/2

RoW

LM-061, Kinase inhibitor

LaNova Medicines Limited

Advanced Tumours

02/23

07/23

NCT04737122: Study of LM-061 in Subjects in Advanced Tumors

Terminated

RoW

LM-061, Kinase inhibitor, Toripalimab

LaNova Medicines Limited

Advanced Tumours

07/22

12/22

tecotabart vedotin (LM-302) / LaNova Medicines Limited

LM302-03-101, NCT06351020: LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Recruiting

375

RoW

LM-302, Apatinib, Irinotecan

LaNova Medicines Zhejiang Co., Ltd.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

08/26

12/26

NCT06587425: The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

RoW

LM-302+Candonilimab+Capecitabine, ADC-Claudin18.2+AK104+Capecitabine

Shanghai Zhongshan Hospital

Gastric or Gastroesophageal Junction Adenocarcinoma

07/25

12/26

NCT05934331: A LM-302 Combined With Toripalimab Phase II Study

Recruiting

276

RoW

LM302+Toripalimab, LM302+JS001

LaNova Medicines Zhejiang Co., Ltd.

Gastric Cancer, Pancreatic Cancer

07/25

01/26

NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Completed

1/2

RoW

LM-302, Toripalimab, Tuoyi

LaNova Australia Pty Limited

Advanced Solid Tumor

11/23

LM302-01-102, NCT05161390: Study of LM-302 in Patients With Advance Solid Tumors

Active, not recruiting

1/2

206

RoW

LM-302 Injection

LaNova Medicines Zhejiang Co., Ltd.

Advanced Solid Tumor

03/25

06/25

NCT05001516: Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed

LM-302

Turning Point Therapeutics, Inc.

Advanced Solid Tumor

01/24

LM-102 / LaNova Medicines Limited

NCT05008445: Study of LM-102 in Patients With Advance Solid Tumors

Terminated

1/2

RoW

LM-102 Injection, LM-102 Injection combined with SOC

LaNova Medicines Development Co., Ltd., Shanghai Zhongshan Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital

Advanced Solid Tumor

02/23

cafelkibart (LM-108) / LaNova Medicines Limited

NCT06873854: A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Not yet recruiting

RoW

LM-108, Toripalimab

LaNova Medicines Limited, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Solid Tumor

01/28

01/30

NCT05255484: Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated

1/2

LM-108, An Anti-PD-1 Antibody

LaNova Medicines Limited

Advanced Solid Tumor

10/23

NCT05199753: Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Recruiting

1/2

RoW

LM-108, An Anti-PD-1 Antibody

LaNova Australia Pty Limited

Advanced Solid Tumor

12/24

NCT06821503: Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Not yet recruiting

1/2

RoW

LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound), Gemcitabine hydrochloride for injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Pancreatic Cancer

12/27

12/28

NCT06825494: Clinical Studies for the Treatment of Advanced Solid Tumors

Recruiting

1/2

134

RoW

LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Advanced Solid Tumor

03/26

09/26

NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Enrolling by invitation

1/2

392

RoW

LM-108, Toripalimab

LaNova Medicines Limited

Advanced Solid Tumor

07/25

10/25

AZD0305 / AstraZeneca

NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Withdrawn

1/2

380

LM-305, Dexamethasone

LaNova Medicines Limited

Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases

12/24

12/25

NCT06106945: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting

1/2

226

Europe, Canada, Japan, US, RoW

AZD0305

AstraZeneca

Multiple Myeloma

03/27

LM-101 / LaNova Medicines Limited

LM101-01-103, NCT05615974: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Recruiting

1/2

139

RoW

LM101, Toripalimab, Rituximab

LaNova Medicines Limited

Malignant Tumors

01/27

01/28

LM-002 / LaNova Medicines Limited

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

LM-061 / LaNova Medicines Limited

NCT04882176: A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Terminated

1/2

RoW

LM-061, Kinase inhibitor

LaNova Medicines Limited

Advanced Tumours

02/23

07/23

NCT04737122: Study of LM-061 in Subjects in Advanced Tumors

Terminated

RoW

LM-061, Kinase inhibitor, Toripalimab

LaNova Medicines Limited

Advanced Tumours

07/22

12/22

tecotabart vedotin (LM-302) / LaNova Medicines Limited

LM302-03-101, NCT06351020: LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Recruiting

375

RoW

LM-302, Apatinib, Irinotecan

LaNova Medicines Zhejiang Co., Ltd.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

08/26

12/26

Recruiting

RoW

LM-302+Candonilimab+Capecitabine, ADC-Claudin18.2+AK104+Capecitabine

Shanghai Zhongshan Hospital

Gastric or Gastroesophageal Junction Adenocarcinoma

07/25

12/26

NCT05934331: A LM-302 Combined With Toripalimab Phase II Study

Recruiting

276

RoW

LM302+Toripalimab, LM302+JS001

LaNova Medicines Zhejiang Co., Ltd.

Gastric Cancer, Pancreatic Cancer

07/25

01/26

NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Completed

1/2

RoW

LM-302, Toripalimab, Tuoyi

LaNova Australia Pty Limited

Advanced Solid Tumor

11/23

LM302-01-102, NCT05161390: Study of LM-302 in Patients With Advance Solid Tumors

Active, not recruiting

1/2

206

RoW

LM-302 Injection

LaNova Medicines Zhejiang Co., Ltd.

Advanced Solid Tumor

03/25

06/25

NCT05001516: Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed

LM-302

Turning Point Therapeutics, Inc.

Advanced Solid Tumor

01/24

LM-102 / LaNova Medicines Limited

NCT05008445: Study of LM-102 in Patients With Advance Solid Tumors

Terminated

1/2

RoW

LM-102 Injection, LM-102 Injection combined with SOC

Advanced Solid Tumor

02/23

cafelkibart (LM-108) / LaNova Medicines Limited

NCT06873854: A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Not yet recruiting

RoW

LM-108, Toripalimab

LaNova Medicines Limited, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Solid Tumor

01/28

01/30

NCT05255484: Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated

1/2

LM-108, An Anti-PD-1 Antibody

LaNova Medicines Limited

Advanced Solid Tumor

10/23

NCT05199753: Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Recruiting

1/2

RoW

LM-108, An Anti-PD-1 Antibody

LaNova Australia Pty Limited

Advanced Solid Tumor

12/24

NCT06821503: Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Not yet recruiting

1/2

RoW

LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound), Gemcitabine hydrochloride for injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Pancreatic Cancer

12/27

12/28

NCT06825494: Clinical Studies for the Treatment of Advanced Solid Tumors

Recruiting

1/2

134

RoW

LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Advanced Solid Tumor

03/26

09/26

NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Enrolling by invitation

1/2

392

RoW

LM-108, Toripalimab

LaNova Medicines Limited

Advanced Solid Tumor

07/25

10/25

AZD0305 / AstraZeneca

NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Withdrawn

1/2

380

LM-305, Dexamethasone

LaNova Medicines Limited

Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases

12/24

12/25

NCT06106945: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting

1/2

226

Europe, Canada, Japan, US, RoW

AZD0305

AstraZeneca

Multiple Myeloma

03/27

LM-101 / LaNova Medicines Limited

LM101-01-103, NCT05615974: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Recruiting

1/2

139

RoW

LM101, Toripalimab, Rituximab

LaNova Medicines Limited

Malignant Tumors

01/27

01/28

LM-002 / LaNova Medicines Limited

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites